HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

TAK-632

Also Known As:

N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo(d)thiazol-2-yl)cyclopropanecarboxamide

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Nitriles: 227
  - TAK-632: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Benzothiazoles: 40
        TAK-632: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzothiazoles: 40
      - TAK-632: 3

Experts

1.	Cai, Zhenyu: 2 articles (01/2019 - 01/2019)
2.	Chen, Xiaofei: 2 articles (01/2019 - 01/2019)
3.	Hu, Longmiao: 2 articles (01/2019 - 01/2019)
4.	Miao, Zhenyuan: 2 articles (01/2019 - 01/2019)
5.	Qin, Xia: 2 articles (01/2019 - 01/2019)
6.	Zhang, Hao: 2 articles (01/2019 - 01/2019)
7.	Zhuang, Chunlin: 2 articles (01/2019 - 01/2019)
8.	Chai, Yifeng: 1 article (01/2019)
9.	Chen, Long: 1 article (01/2019)
10.	Cong, Hui: 1 article (01/2019)

Related Diseases

1.	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 01/01/2019 - "A mouse model of TNF-α-induced systemic inflammatory response syndrome (SIRS) was further used to explore the role of TAK-632 in protecting against necroptosis-associated inflammation in vivo. " 01/01/2019 - "In a tumor necrosis factor-induced systemic inflammatory response syndrome model, it significantly protected mice from hypothermia and death at a dose of 5 mg/kg, which was much more effective than TAK-632. "
2.	Melanoma (Melanoma, Malignant) 12/01/2013 - "Our findings characterize the unique features of TAK-632 as a pan-RAF inhibitor and provide rationale for its further investigation in NRAS-mutated melanoma and a subset of BRAF-mutated melanomas refractory to BRAF inhibitors." 12/01/2013 - "As a result, TAK-632 demonstrates potent antiproliferative effects both on NRAS-mutated melanoma cells and BRAF-mutated melanoma cells with acquired resistance to BRAF inhibitors through NRAS mutation or BRAF truncation. " 12/01/2013 - "Our analysis using RNAi and TAK-632 in preclinical models reveals that the MAPK pathway of NRAS-mutated melanoma cells is highly dependent on RAF. " 12/01/2013 - "Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma."
3.	Inflammation (Inflammations) 01/01/2019 - "A mouse model of TNF-α-induced systemic inflammatory response syndrome (SIRS) was further used to explore the role of TAK-632 in protecting against necroptosis-associated inflammation in vivo. "
4.	Hypothermia 01/01/2019 - "In a tumor necrosis factor-induced systemic inflammatory response syndrome model, it significantly protected mice from hypothermia and death at a dose of 5 mg/kg, which was much more effective than TAK-632. "

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)